Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects

To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy male subjects. [14C]-Labeled naloxegol (27 mg, 3.43 MBq) was administered as an oral solution to 6 fasted subjects. Blood, fecal, and urine sam...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of clinical pharmacology and therapeutics Vol. 53; no. 10; p. 838
Main Authors Bui, Khanh, She, Fahua, Hutchison, Michael, Brunnström, Åsa, Sostek, Mark
Format Journal Article
LanguageEnglish
Published Germany 01.10.2015
Subjects
Online AccessGet more information

Cover

Loading…
Abstract To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy male subjects. [14C]-Labeled naloxegol (27 mg, 3.43 MBq) was administered as an oral solution to 6 fasted subjects. Blood, fecal, and urine samples were collected predose and at various intervals postdose. Naloxegol and its metabolites were quantified or identified by liquid chromatography with radiometric or mass spectrometric detection. Pharmacokinetic parameters were calculated for each subject, and metabolite identification was performed by liquid chromatography with parallel radioactivity measurement and mass spectrometry. Naloxegol was rapidly absorbed, with a maximum plasma concentration (geometric mean) of 51 ng/mL reached before 2 hours after dosing. A second peak in the observed naloxegol and [14C] plasma concentration-time profiles was observed at ~3 hours and was likely due to enterohepatic recycling of parent naloxegol. Distribution to red blood cells was negligible. Metabolism of [14C]-naloxegol was rapid and extensive and occurred via demethylation and oxidation, dealkylation, and shortening of the polyethylene glycol chain. Mean cumulative recovery of radioactivity was 84.2% of the total dose, with ~68.9% recovered within 96 hours of dosing. Fecal excretion was the predominant route of elimination, with mean recoveries of total radioactivity in feces and urine of 67.7% and 16.0%, respectively. Unchanged naloxegol accounted for ~1/4 of the radioactivity recovered in feces. Naloxegol was rapidly absorbed and cleared via metabolism, with predominantly fecal excretion of parent and metabolites.
AbstractList To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy male subjects. [14C]-Labeled naloxegol (27 mg, 3.43 MBq) was administered as an oral solution to 6 fasted subjects. Blood, fecal, and urine samples were collected predose and at various intervals postdose. Naloxegol and its metabolites were quantified or identified by liquid chromatography with radiometric or mass spectrometric detection. Pharmacokinetic parameters were calculated for each subject, and metabolite identification was performed by liquid chromatography with parallel radioactivity measurement and mass spectrometry. Naloxegol was rapidly absorbed, with a maximum plasma concentration (geometric mean) of 51 ng/mL reached before 2 hours after dosing. A second peak in the observed naloxegol and [14C] plasma concentration-time profiles was observed at ~3 hours and was likely due to enterohepatic recycling of parent naloxegol. Distribution to red blood cells was negligible. Metabolism of [14C]-naloxegol was rapid and extensive and occurred via demethylation and oxidation, dealkylation, and shortening of the polyethylene glycol chain. Mean cumulative recovery of radioactivity was 84.2% of the total dose, with ~68.9% recovered within 96 hours of dosing. Fecal excretion was the predominant route of elimination, with mean recoveries of total radioactivity in feces and urine of 67.7% and 16.0%, respectively. Unchanged naloxegol accounted for ~1/4 of the radioactivity recovered in feces. Naloxegol was rapidly absorbed and cleared via metabolism, with predominantly fecal excretion of parent and metabolites.
Author Bui, Khanh
Sostek, Mark
Hutchison, Michael
She, Fahua
Brunnström, Åsa
Author_xml – sequence: 1
  givenname: Khanh
  surname: Bui
  fullname: Bui, Khanh
– sequence: 2
  givenname: Fahua
  surname: She
  fullname: She, Fahua
– sequence: 3
  givenname: Michael
  surname: Hutchison
  fullname: Hutchison, Michael
– sequence: 4
  givenname: Åsa
  surname: Brunnström
  fullname: Brunnström, Åsa
– sequence: 5
  givenname: Mark
  surname: Sostek
  fullname: Sostek, Mark
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26329350$$D View this record in MEDLINE/PubMed
BookMark eNo1j8tKxDAYRrMYcS4KPoHkAaaa_E2bZjkUbzCgC12JDLn8cTqkTWlamHl7kdHVx-HAgW9JZl3skJAbzu4KwcV9_QYMQJYzsmBKlBlXZTEny5QOjEFRSHVJ5lDmoPKCLYjZmBSHfmxit6auSePQmOlMLY7axNCkdk115yge7YC_ikZPP7mov7KgDQZ0tNMhHvE7Btp0dI86jPsTTZM5oB3TFbnwOiS8_tsV-Xh8eK-fs-3r00u92WY2lzBmEiulwVuWc6ukt1payXN0zCFWBnihGViBvjLC65wL5z0qzcF6W1Xcc1iR23O3n0yLbtcPTauH0-7_LPwAFFdXBQ
CitedBy_id crossref_primary_10_5056_jnm18079
crossref_primary_10_1002_cpdd_335
crossref_primary_10_1093_jat_bkx104
crossref_primary_10_1016_j_ejps_2018_02_008
crossref_primary_10_1002_psp4_12229
crossref_primary_10_1007_s11912_015_0481_x
crossref_primary_10_1002_jcph_693
crossref_primary_10_1016_j_clinbiochem_2019_03_006
crossref_primary_10_1097_FAD_0000000000000023
crossref_primary_10_1002_psp4_12070
crossref_primary_10_1007_s40262_016_0479_z
crossref_primary_10_1177_1756283X16648869
crossref_primary_10_4155_bio_2016_0253
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.5414/CP202276
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 26329350
Genre Research Support, Non-U.S. Gov't
Journal Article
Clinical Trial, Phase I
GroupedDBID ---
.GJ
36B
53G
5GY
7X7
88E
8FI
8FJ
ABJNI
ABUWG
ACGFO
ACGFS
ADBBV
AENEX
AFFNX
AFKRA
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
DLWAR
EBS
ECM
EIF
EJD
EMB
EMOBN
F5P
FYUFA
HMCUK
M1P
MK0
NPM
P2P
PHGZT
PQQKQ
PROAC
PSQYO
SJN
SV3
UKHRP
VDS
ZGI
ZXP
~4P
ID FETCH-LOGICAL-c372t-7e89a2fc031c97fca7c713ed0dee8b215a02c4ef8b4fa314dffe9a12cfc881f12
ISSN 0946-1965
IngestDate Thu Apr 03 06:54:07 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c372t-7e89a2fc031c97fca7c713ed0dee8b215a02c4ef8b4fa314dffe9a12cfc881f12
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/4564822
PMID 26329350
ParticipantIDs pubmed_primary_26329350
PublicationCentury 2000
PublicationDate 2015-10-01
PublicationDateYYYYMMDD 2015-10-01
PublicationDate_xml – month: 10
  year: 2015
  text: 2015-10-01
  day: 01
PublicationDecade 2010
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle International journal of clinical pharmacology and therapeutics
PublicationTitleAlternate Int J Clin Pharmacol Ther
PublicationYear 2015
SSID ssj0025579
Score 2.1575322
Snippet To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy...
SourceID pubmed
SourceType Index Database
StartPage 838
SubjectTerms Aged
Carbon Radioisotopes
Humans
Male
Middle Aged
Morphinans - adverse effects
Morphinans - pharmacokinetics
Narcotic Antagonists - pharmacokinetics
Polyethylene Glycols - adverse effects
Polyethylene Glycols - pharmacokinetics
Tissue Distribution
Title Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/26329350
Volume 53
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELa2cOGCKO9SkA-0lyaQh5M4x7aAKiTQSmylSghVjh9spTZZkV2pyx_j7zETO4lZHgIuUTZeJbG_b-2Z2ZnPhDxnkTRcqSQERA2GbvKwVEKFqmCiyjSsEd1mMO_e5yen7O1ZdjaZfPOyllbL6oX8-su6kv9BFa4Brlgl-w_IDjeFC3AO-MIREIbjX2F8WLXNl-43jyOlUAPXbV-Fn6_0EhC-xNQKl6KpryUWLVoTcS87itnxXvYqBCLA4qMO4HnNtf7coAyHK5BcH7SrCkM1rW_F_hhG9MQnhjrLxaiIve6TNPs6rzEwv7KpBHNRD0HpD3ObbyzmKzFSDqh10f6c59-FEcACh37jH_5HeddTPOVZK_yARpwNqXFDZJLlIQod-pO0VRTuyRh5Uy636jCbSwFub44Sw9MERRJz_ysA4uKqowSK1ZepVb79c-uGKHfftEW2wD3B_VYxSOT8_CxzEo-uH1bzGF_oZf86qEHtbrHhz3R2zewOue0cEnpo2bVNJrq-S_anFr91QGcecAHdp1MP2XukGikYUJ-AAR3pF1BgAB3IRxtDPwL1PvXEowPx6EVNHfFoT7z75PTN69nxSei27QhlWiTLsNC8FImRsFzIsjBSFLKIU60ipTWvwMQUUSKZNrxiRqQxU8boUsSJNJLz2MTJA3Kjbmr9iNBMFIWKcxlxUTBdYuBbK8ONBi-iUil7TB7asTtfWG2W835Ud37b8oTcGlm3S24amAz0U7Asl9WzDsfvmAl6xQ
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absorption%2C+distribution%2C+metabolism%2C+and+excretion+of+%5B14C%5D-labeled+naloxegol+in+healthy+subjects&rft.jtitle=International+journal+of+clinical+pharmacology+and+therapeutics&rft.au=Bui%2C+Khanh&rft.au=She%2C+Fahua&rft.au=Hutchison%2C+Michael&rft.au=Brunnstr%C3%B6m%2C+%C3%85sa&rft.date=2015-10-01&rft.issn=0946-1965&rft.volume=53&rft.issue=10&rft.spage=838&rft_id=info:doi/10.5414%2FCP202276&rft_id=info%3Apmid%2F26329350&rft_id=info%3Apmid%2F26329350&rft.externalDocID=26329350
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0946-1965&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0946-1965&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0946-1965&client=summon